新型口服抗凝药在慢性肾病患者中的应用  

Application of new orally anticoagulants in patients with chronic kidney disease

作　　者：汪秀衡 吴洁[2] 胡恒境[1,2] WANG Xiu-heng;WU Jie;HU Heng-jing(Postdoctoral Research Station of Basic Medicine, University of South China;Department of Cardiology Lab, the First Affiliated Hospital of University of South China;Department of Nuclear Medicine Lab, the First Affiliated Hospital of University of South China, Hengyang 421000, China)

机构地区：[1]南华大学基础医学博士后流动站 [2]南华大学附属第一医院心内科 [3]南华大学附属第一医院核医学科,湖南衡阳421000

出　　处：《基础医学与临床》2020年第8期1103-1108,共6页Basic and Clinical Medicine

基　　金：国家自然科学基金(81700306);湖南省自然科学基金(2018JJ3469);中国博士后科学基金(2017M622588);湖南省卫生健康委(C2019115)。

摘　　要：新型口服抗凝剂(NOACs)是一种新研发的凝血因子抑制剂,在各种血栓事件及缺血性心血管事件中发挥着重要的作用,但其在慢性肾病(CKD)3~5期患者中的使用仍存在争议。对不同分期CKD患者推荐使用NOACs、监测评价NOACs所致抗凝相关肾病及NOACs临床应用。Novel oral anticoagulants(NOVACs)as blood coagulation factor inhibitors have exhibited pivotal role in thromboembolic event and ischemic cardiovascular disease.Nevertheless,it's application in chronic kidney disease(CKD)patients of stage 3-5 remains controversial.This paper reviewed currently recommended usage of NOACs in CKD patients of stage 3-5 in the evaluation of anticoagulation related nephropathy,clinical monitoring and assessment of NOACs.

关 键 词：慢性肾病 新型口服抗凝药 栓塞 

分 类 号：R54[医药卫生—心血管疾病]